Article: PerkinElmer Receives FDA Clearance for World's First Tandem Mass Spectrometry Newborn Screening System.

BOSTON -- PerkinElmer, Inc. (NYSE: PKI):

--Kit Screens for Metabolic Disorders; Enables Early Detection and Intervention

--Analyzes More Than 40 Disease Markers with a Single Blood Sample

PerkinElmer, Inc. (NYSE: PKI), a leading provider of drug discovery, life science research and analytical solutions, today announced that it has received clearance from the U.S. Food and Drug Administration for its NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit. PerkinElmer now has the world's first kit cleared by the FDA for use in the global standardization of Metabolic Screening with Tandem Mass Spectrometry.

Newborn screening ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!